Key Takeaways

  • Bringing a single compound through FDA approval costs between $200 million and $250 million, making pure nonprofit drug development impossible to scale.
  • Transcend Therapeutics selected methylone over MDMA because methylone avoids severe serotonin depletion, enabling safe once-a-week clinical dosing.
  • First-mover advantage is dangerous in novel regulatory environments. As Ryan puts it, “The early bird gets the worm, but the second mouse gets the cheese.”
  • Transcend operates as a Public Benefit Corporation, committing 10% of founder gains ($20 million over nine months) back into nonprofit psychedelic initiatives.
  • While the psychedelic sector focuses politically on military veterans, sexual assault is the primary source of PTSD; Transcend's clinical trials enrolled 60% women.

The Real Economics of Biotech

Nonprofit purism sounds noble until you look at drug development costs. Developing treatments for mental illness requires enormous capital that philanthropy cannot provide alone.

Kevin Ryan is blunt about the math: “It takes roughly $200 to $250 million to get one compound through the FDA process. And I wish that were less, but it is what it is right now. And we're not going to be able to raise that money from a nonprofit point of view.”

Transcend solved this tension by organizing as a Public Benefit Corporation. The corporate structure allows the team to raise standard institutional venture capital while legally binding the company to a social mission. Ryan and co-founder Blake Mandell pledged 10% of their personal founder gains to a dedicated foundation. “Blake and I will be giving out that money,” Ryan notes. “And so we will be giving $20 million in the next 9 months.”

Why Methylone Beats MDMA

Being first to clinical trials is rarely the winning strategy in biotech. Pioneer organizations like MAPS spent decades fighting regulatory battles for MDMA. That groundwork paved the regulatory road, but MDMA carries severe physiological limitations.

MDMA heavily depletes serotonin and requires extended hours in a clinic, making frequent administration dangerous and expensive. Transcend chose methylone instead.

“You can take methylone once a week in our trials,” Ryan explains. “You actually can't take MDMA once a week. It's a little bit more toxic. It depletes your serotonin a little bit more.”

By selecting a compound with a shorter duration of action and a cleaner recovery profile, Transcend reduced clinical overhead and created a protocol patients can repeat weekly. Ryan embraces being the follower rather than the pioneer: “There's a saying, the early bird gets the worm, but the second mouse gets the cheese. Sometimes it's better to be the second mouse.”

Broadening the Patient Base

The biotech sector often builds its public relations strategy around military veterans because veteran PTSD receives bipartisan political support. Ryan points out that this narrative obscures the true demographic reality of trauma.

“We focus on veterans for PTSD for political reasons. We being the entire industry,” Ryan says. “The number one source is sexual assault. And that's why our trials were actually 60% women.”

Designing clinical trials around the actual patient population rather than political talking points shifts trial recruitment, clinician training, and therapy protocols. Building a lasting medical company requires facing real clinical demographics from day one.

What to Do With This

Audit the ownership structure of your next entity before you close your seed round. If your business solves a public health or social problem, incorporate as a Public Benefit Corporation and write a fixed percentage of founder equity into a binding pledge for grassroots access.